Validation of a Lung Inflammation Model in Healthy Volunteers by Radiological Tools and Glucocorticoid Treatment

Inclusion Criteria: * Signed informed consent obtained before any trial-related activities. (Trial activities are any procedure that would not have been performed during normal management of the subject). * Nonsmoker * Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant * Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant * If female and of childbearing potential and subjects agrees to employ adequate birth control measures (e. g. oral contraceptives, barrier method) * Negative urine pregnancy test Exclusion Criteria: * Known or suspected allergy to trial product or related products * Pregnancy or Lactation * Treatment with an investigational drug within three weeks prior to this trial * Participation in an LPS trial within the last 6 weeks * Smoking * History of relevant cardiac arrhythmia * Preexisting open or closed angle glaucoma * History of Osteoporosis, Cushing´s syndrome, gastro-duodenal ulcera, cardiovascular disease, vasculitis, diabetes mellitus, hypertension, brain tumor or history of neurosurgery * Systemic tuberculosis * Hemorrhagic diathesis * Relevant liver or kidney dysfunction * Regular use of medication or abuse of alcohol unless considered clinically relevant * Use of any medication within one week prior to the first trial day * Symptoms of a clinically relevant illness in the 3 weeks before the first trial day * Excessive sporting activities * Rosacea * Subjects on Monoamine oxidase inhibitors (should be stopped for at least two to three weeks before dihydrocodeine treatment is initiate) * Known acute or active hepatic disease within the past 3 months * A platelet count \< 100,000 x 106/L, prothrombin time \> 1.5, liver enzymes\> 3 times the upper normal limit * Having received a vaccination up to 8 weeks before the trial